Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.44 |
| ▸ | PDE4A | P27815 | 6/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.44 |
| ▸ | QDPR | P09417 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20790105 | 0.89 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4DQDPR | |
| SCHEMBL31045596 | 0.87 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DQDPR | |
| SCHEMBL31045649 | 0.80 | LPAR1 (0.48) | — | |
| SCHEMBL31045810 | 0.78 | MEN1 (0.43) | — | |
| SCHEMBL31045886 | 0.78 | ALDH1A1 (0.42) | — | |
| SCHEMBL20789882 | 0.77 | PDE4B (0.36) | PDE4BPDE4APDE4CPDE4DQDPR | |
| SCHEMBL20790143 | 0.76 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DQDPR | |
| SCHEMBL20789988 | 0.76 | PDE4B (0.37) | PDE4BPDE4APDE4CPDE4DQDPR | |
| SCHEMBL31045701 | 0.76 | ALDH1A1 (0.44) | — | |
| SCHEMBL31045563 | 0.75 | RXRA (0.40) | PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680336-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024196788-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | PDE4B 1817/4885PDE4A 1795/4885PDE4C 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.